{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:29:43Z","timestamp":1784604583840,"version":"3.55.0"},"reference-count":65,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merz Pharmaceuticals, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>The pooled incidences of treatment-emergent adverse events (TEAEs) were examined by indication using the integrated clinical database of Merz-sponsored, placebo-controlled, or repeat-dose studies of incobotulinumtoxinA in adults with cervical dystonia, blepharospasm, limb spasticity, sialorrhea, or essential tremor of the upper limb. Overall incidences of TEAEs, serious TEAEs, TEAEs leading to discontinuation, fatal TEAEs, TEAEs of special interest (TEAESIs; indicating possible toxin spread), and treatment-related (TR) events were determined for incobotulinumtoxinA and placebo after a single injection and for repeated dose cycles of incobotulinumtoxinA. The most frequent events after a single dose of incobotulinumtoxinA are summarized. After a single cycle, incidences of overall TEAEs were similar between incobotulinumtoxinA and the placebo in most indications, although between-indication differences were observed. Few TEAEs led to incobotulinumtoxinA discontinuation; there were no fatal TEAEs with incobotulinumtoxinA. In general, repeated cycles did not increase the incidence of any event. The most frequent TR-TEAEs were indication-dependent, including dysphagia for indications affecting the head or neck. The TR-TEAESIs across all indications were most commonly muscular weakness, dysphagia and dry mouth. Overall, the results of this pooled analysis support and extend the favorable safety and tolerability profile of incobotulinumtoxinA for the treatment of adult neurological disorders established by individual clinical studies.<\/jats:p>","DOI":"10.3390\/toxins15060353","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T10:51:56Z","timestamp":1684839116000},"page":"353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"Wolfgang H.","family":"Jost","sequence":"first","affiliation":[{"name":"Parkinson-Klinik Ortenau, 77709 Wolfach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-3241","authenticated-orcid":false,"given":"Petr","family":"Ka\u0148ovsk\u00fd","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry and University Hospital, Palack\u00fd University Olomouc, 779 00 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hast","sequence":"additional","affiliation":[{"name":"Merz Pharmaceuticals, LLC, Raleigh, NC 27615, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hanschmann","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Althaus","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7953","authenticated-orcid":false,"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[{"name":"Kansas City Bone and Joint Clinic, Overland Park, KS 66211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"ref_1","unstructured":"(2022, August 08). Merz Pharmaceuticals GmbH, Xeomin Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125360s074lbl.pdf."},{"key":"ref_2","unstructured":"Merz Pharma UK Ltd (2022, August 08). Xeomin 200 Units Powder for Solution for Injection. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/2162\/smpc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_4","first-page":"100142","article-title":"Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study","volume":"6","author":"Comella","year":"2022","journal-title":"Clin. Park Relat. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(\u00ae)) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J. Neural. Transm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxin A injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Xeomin US Blepharospasm Study Group. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(\u00ae)) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J. Neural. Transm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1007\/s12325-020-01427-6","article-title":"IncobotulinumtoxinA for the treatment of blepharospasm in toxin-na\u00efve subjects: A multi-center, double-blind, randomized, placebo-controlled trial","volume":"37","author":"Mitsikostas","year":"2020","journal-title":"Adv Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01354.x","article-title":"Efficacy and safety of NT 201 for upper limb spasticity of various etiologies--a randomized parallel-group study","volume":"122","author":"Barnes","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Slawek","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Slawek","year":"2011","journal-title":"J. Rehabil. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mus.24776","article-title":"Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity","volume":"53","author":"Elovic","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12325-018-0833-7","article-title":"IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: Results from the open-label extension period of a phase 3 study","volume":"36","author":"Marciniak","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00415-020-09777-5","article-title":"J-PURE Study Group. Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: Results from a randomized, double-blind, placebo-controlled study (J-PURE)","volume":"267","author":"Masakado","year":"2020","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1982","DOI":"10.1212\/WNL.0000000000007368","article-title":"SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea","volume":"92","author":"Jost","year":"2019","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.parkreldis.2019.11.024","article-title":"Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks","volume":"70","author":"Jost","year":"2020","journal-title":"Parkinsonism. Relat. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.22368","article-title":"Relationship between various clinical outcome assessments in patients with blepharospasm","volume":"24","author":"Jankovic","year":"2009","journal-title":"Mov Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1212\/WNL.0000000000003789","article-title":"TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study","volume":"88","author":"Wissel","year":"2017","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"832937","DOI":"10.3389\/fneur.2022.832937","article-title":"Efficacy and safety of IncobotulinumtoxinA in the treatment of lower limb spasticity in Japanese subjects","volume":"13","author":"Masakado","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jog, M., Lee, J., Scheschonka, A., Chen, R., Ismail, F., Boulias, C., Hobson, D., King, D., Althaus, M., and Simon, O. (2020). Tolerability and efficacy of customized incobotulinumtoxinA injections for essential tremor: A randomized, double-blind, placebo-controlled study. Toxins, 12.","DOI":"10.3390\/toxins12120807"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1097\/DSS.0000000000001409","article-title":"Safety of incobotulinumtoxinA in the treatment of facial lines: Results from a pooled analysis of randomized, prospective, controlled clinical studies","volume":"43","author":"Coleman","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e4228","DOI":"10.1097\/GOX.0000000000004228","article-title":"The Multispecialty Toxin: A literature review of botulinum toxin","volume":"10","author":"Bach","year":"2022","journal-title":"Plast Reconstr. Surg. Glob. Open"},{"key":"ref_25","first-page":"CD004900","article-title":"Botulinum toxin type A therapy for blepharospasm","volume":"11","author":"Duarte","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ruiz-Roca, J.A., Pons-Fuster, E., and Lopez-Jornet, P. (2019). Effectiveness of the botulinum toxin for treating sialorrhea in patients with Parkinson\u2019s disease: A systematic review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030317"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ene.15083","article-title":"Efficacy and safety of botulinum toxin for treating sialorrhea: A systematic review and meta-analysis","volume":"29","author":"Yu","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.4081\/ni.2015.5886","article-title":"Botulinum Neurotoxin Type A in Neurology: Update","volume":"7","author":"Orsini","year":"2015","journal-title":"Neurol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxicon.2015.08.014","article-title":"Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview","volume":"107","author":"Petracca","year":"2015","journal-title":"Toxicon"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3109\/21678421.2013.830312","article-title":"Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: Review of the literature and a proposal for tailored treatment","volume":"14","author":"Stokholm","year":"2013","journal-title":"Amyotroph Lateral Scler Front. Degener."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"key":"ref_32","first-page":"CD008624","article-title":"Interventions for drooling in children with cerebral palsy","volume":"11","author":"Walshe","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1469-8749.2012.04370.x","article-title":"Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: A systematic review","volume":"54","author":"Rodwell","year":"2012","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_34","first-page":"CD004312","article-title":"Botulinum toxin type A versus anticholinergics for cervical dystonia","volume":"4","author":"Rodrigues","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14740338.2021.1915282","article-title":"Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: A critical reappraisal","volume":"20","author":"Marsili","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.toxicon.2018.01.018","article-title":"Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity\u2013Insights from recent studies","volume":"147","author":"Wissel","year":"2018","journal-title":"Toxicon"},{"key":"ref_37","first-page":"CD004314","article-title":"Botulinum toxin type A versus botulinum toxin type B for cervical dystonia","volume":"10","author":"Duarte","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00415-016-8050-2","article-title":"A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia","volume":"263","author":"Han","year":"2016","journal-title":"J. Neurol."},{"key":"ref_39","first-page":"725","article-title":"Patient considerations in the treatment of cervical dystonia: Focus on botulinum toxin type A","volume":"9","author":"Mills","year":"2015","journal-title":"Patient Prefer. Adherence"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5603\/PJNNS.a2021.0032","article-title":"Safety and efficacy of Botulinum toxin type A preparations in cerebral palsy\u2014An evidence-based review","volume":"55","author":"Bonikowski","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Intiso, D., Simone, V., Bartolo, M., Santamato, A., Ranieri, M., Gatta, M.T., and Di Rienzo, F. (2020). High dosage of botulinum toxin type A in adult subjects with spasticity following acquired central nervous system damage: Where are we at?. Toxins, 12.","DOI":"10.3390\/toxins12050315"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2015.01.033","article-title":"Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke","volume":"350","author":"Santamato","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome","volume":"67","author":"Esquenazi","year":"2013","journal-title":"Toxicon"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1468-1331.2010.03130.x","article-title":"Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: International consensus statement","volume":"17","author":"Novak","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mds.22452","article-title":"Botulinum neurotoxins for post-stroke spasticity in adults: A systematic review","volume":"24","author":"Elia","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00023210-200822090-00002","article-title":"Use of botulinum toxin A in adult neurological disorders: Efficacy, tolerability and safety","volume":"22","year":"2008","journal-title":"CNS Drugs."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00002018-200629010-00003","article-title":"Botulinum toxin treatment of adult spasticity: A benefit-risk assessment","volume":"29","author":"Sheean","year":"2006","journal-title":"Drug Saf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","article-title":"Safety and efficacy of botulinum toxin type A following long-term use","volume":"13","author":"Naumann","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/ajhp\/61.suppl_6.S11","article-title":"Botulinum neurotoxin serotype A: A clinical update on non-cosmetic uses","volume":"61","author":"Charles","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_51","first-page":"CD003633","article-title":"Botulinum toxin type A therapy for cervical dystonia","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00702-007-0869-3","article-title":"Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity","volume":"115","author":"Rosales","year":"2008","journal-title":"J. Neural. Transm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40265-018-1042-z","article-title":"Botulinum toxin type A for the treatment of lower limb spasticity after stroke","volume":"79","author":"Santamato","year":"2019","journal-title":"Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Berweck, S., Banach, M., Gaebler-Spira, D., Chambers, H.G., Schroeder, A.S., Geister, T.L., Althaus, M., Hanschmann, A., Vacchelli, M., and Bonfert, M.V. (2022). Safety profile and lack of immunogenicity of incobotulinumtoxinA in pediatric spasticity and sialorrhea: A pooled analysis. Toxins, 14.","DOI":"10.3390\/toxins14090585"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00415-022-11395-2","article-title":"Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin","volume":"270","author":"Hefter","year":"2022","journal-title":"J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"neutralizing antibody and botulinum toxin therapy: A systematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2016","journal-title":"Neurotox Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to botulinum toxin type A: A systematic review with meta-analysis across therapeutic indications","volume":"42","author":"Rahman","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2109","DOI":"10.1212\/WNL.0000000000009444","article-title":"Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy","volume":"94","author":"Walter","year":"2020","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1007\/s12325-021-01882-9","article-title":"Immunogenicity of botulinum toxin formulations: Potential therapeutic implications","volume":"38","author":"Carr","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2019). Immunogenicity associated with botulinum toxin treatment. Toxins, 11.","DOI":"10.3390\/toxins11090491"},{"key":"ref_64","unstructured":"Hefter, H., and Samadzadeh, S. (2022). Botulinum Toxin\u2014Recent Topics and Applications, IntechOpen."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov. Disord."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/6\/353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:40:30Z","timestamp":1760125230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/6\/353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["toxins15060353"],"URL":"https:\/\/doi.org\/10.3390\/toxins15060353","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}